Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Change in Inventory: 2022-2025

Historic Change in Inventory for Axsome Therapeutics (AXSM) over the last 3 years, with Sep 2025 value amounting to $5.0 million.

  • Axsome Therapeutics' Change in Inventory rose 487.73% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 170.28%. This contributed to the annual value of -$744,000 for FY2024, which is 109.12% down from last year.
  • As of Q3 2025, Axsome Therapeutics' Change in Inventory stood at $5.0 million, which was up 181.04% from $1.8 million recorded in Q2 2025.
  • Axsome Therapeutics' 5-year Change in Inventory high stood at $5.0 million for Q3 2025, and its period low was -$1.7 million during Q3 2023.
  • In the last 3 years, Axsome Therapeutics' Change in Inventory had a median value of $1.1 million in 2024 and averaged $1.3 million.
  • Per our database at Business Quant, Axsome Therapeutics' Change in Inventory slumped by 681.82% in 2023 and then spiked by 487.73% in 2025.
  • Axsome Therapeutics' Change in Inventory (Quarterly) stood at $1.3 million in 2022, then surged by 269.74% to $4.9 million in 2023, then slumped by 76.90% to $1.1 million in 2024, then spiked by 487.73% to $5.0 million in 2025.
  • Its Change in Inventory stands at $5.0 million for Q3 2025, versus $1.8 million for Q2 2025 and $249,000 for Q1 2025.